Dr. Herbert Loong






Name


Herbert Ho-fung LOONG

Chinese Name


龙浩锋

Qualifications


MBBS(HK), PDipMDPath(HK), MRCP(UK), FHKCP, FHKAM(Medicine)

Title


Associate Professor (Clinical) – Department of Clinical Oncology
Deputy Medical Director – Phase 1 Clinical Trials Centre

Email


h_loong@clo.cuhk.edu.hk

Specific Research / Sites of Interest


Sarcoma Medical Oncology

Neuro-oncology

Thoracic Oncology

Melanoma

Experimental Therapeutics / Early Phase Clinical Trials


Short Biography


Dr. Herbert Loong obtained his medical degree with a Distinction in Surgery from The University of Hong Kong in 2003. He subsequently completed his postgraduate internal medicine and medical oncology training in Queen Elizabeth Hospital and Prince of Wales Hospital in Hong Kong. He was admitted as a Member of the Royal College of Physicians (United Kingdom) in 2006 and a Fellow of the Hong Kong College of Physicians and Hong Kong Academy of Medicine in 2010.
He has completed a Fellowship in Drug Development at Princess Margaret Cancer Centre in Toronto, Canada with special focuses on Experimental Therapeutics, Sarcoma Medical Oncology and Neuro-oncology.
Dr. Loong joined The Chinese University of Hong Kong (CUHK) in March 2014 and is currently an Assistant Professor in the Department of Clinical Oncology, CUHK and the Deputy Medical Director of the Phase 1 Clinical Trials Centre, CUHK. He is also the Convenor of the Adult Sarcoma Multi-Disciplinary Tumour Board at Prince of Wales Hospital.
His academic accolades include being the recipient of the Hong Kong Society for Neuro-oncology Traveling Scholarship in 2015 & 2016, an American Society of Clinical Oncology (ASCO) Merit Award in 2014, European Cancer Congress Fellowship Grant in 2013, European Society for Medical Oncology (ESMO) Preceptorship Award in 2012 & 2013, as well as an ESMO Translational Research Unit Visit Scholarship in 2012.

Most Representative Publications


Choy CT, Wong CH, Loong HH. Low expressions of ASS1 and OTC in glioblastoma suggest the potential clinical use of recombinant human arginase (rhArg). J Neurooncol 2016; 129: 579-581.

Loong HH, Chan AC, Wong AC. Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous Histologies. J Cancer 2016; 7: 268-275.

Mok TS, Loong HH. Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer? Lancet 2016; 387: 1488-1490.

Loong HH, Mok K, Leung LK, Mok TS. Crizotinib in the management of advanced-stage non-small-cell lung cancer. Future Oncol 2015; 11: 735-745.

Loong HH, Winquist E, Waldron J et al. Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx. Eur J Cancer 2014; 50: 2263-2270.

Mok TS, Loong HH. A REVELation in non-small-cell lung cancer treatment? Lancet 2014; 384: 640-642.

Loong HH, Mok TS. Lung cancer: dropping bars or rising hoops--phase III outcomes of NSCLC. Nat Rev Clin Oncol 2014; 11: 381-382.

Loong HH, Yeo W. Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma. Onco Targets Ther 2014; 7: 575-585.

Loong HH, Chan AT. Controversies in the systemic treatment of nasopharyngeal carcinoma. Oral Oncol 2014; 50: 785-790.

Loong HH, Siu LL. Selecting the best drugs for phase I clinical development and beyond. Am Soc Clin Oncol Educ Book 2013; 469-473.